http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
투석치료를 받는 만성신부전 환자의 빈혈에 대한 유전자 재조합 인 에리트로포이에틴(에스포젠)의 임상효과
안규리(Curie Ahn),오하영(Ha Young Oh),박정식(Jung Sik Park),정우경(Woo Kyung Chung),호지숙(Gee Suk Ho),허우성(Woo Sung Huh) 대한신장학회 2000 Kidney Research and Clinical Practice Vol.19 No.2
N/A We conducted a multicenter clinical trial to evaluate the efficacy and safety of recombinant human erythropoietin(Espogen, LG Chemical Ltd.) in the anemic patients of chronic renal failure undergoing dialysis. The patients were end-stage renal disease who were undergoing hemodialysis or peritonea1 dialysis for 3 months or longer and they had less than 8g/dL of hemoglobin and more than 100ng/mL of serum ferritin. Hemodialysis patients were administered 150unit/kg/week of recombinant human erythropoietin as initial dose, and peritoneal dialysis patients 50unitAg, twice per week. We examined hemoglobin value every other week and adjusted the dose in order to maintain hemoglobin level as 10-llg/dL. We enrolled 64 patients and analysed 54 cases in the final. 96.3%(52/54) of patients showed increase by more than 1.0g/dL and the others in- crease by more than 0.5g/dL. Baseline hemoglobin, hematocrit were 7.11±0.85g/dL, 21.3±2.6% and final level were 10.42±1.31g/dL, 31.9±3.5%(p=0.0001), respectively. Reticulocyte was increased after 2 weeks of administration from 0.90±0.74% to 2.45±0.84% The adverse effects included hypertension, headache, increased potassium and phosphate level so required regular monitoring. Therefore we showed that Es-pogen was effective in correcting the anemia of chronic renal failure and didn't have any particular adverse effects.
ADPKD 낭종액에서의 사이토카인 Profile 에 대한 연구
이중건(Jung Geon Lee),안규리(Curie Ahn),윤성철(Sung Chul Yoon),박종훈(Jong Hoon Park),문창숙(Chang Suk Moon),노진주(Jin Ju No),송은경(Eun Kyeung Song),김연수(Yon Su Kim),한진석(Jin Suk Han),김성권(Suhng Gwon Kim),이정상(Jung Sang Lee 대한신장학회 2002 Kidney Research and Clinical Practice Vol.21 No.5
N/A N/A
부신피질 호르몬제로 치료중인 결체조직 질환 환자에서의 조갑 백선
조광현(Kwang Hyun Cho),정진호(Jin Ho Chung),이유신(Yoo Shin Lee),안규리(Curie Ahn),김의종(Eui Chong Kim) 대한피부과학회 1986 대한피부과학회지 Vol.24 No.5
We examined several kinds of immunocompromied patients for onyr,homycosis. The incidence of onychomycosis in the patients with connective tissue disease treated with corticosteroid was significantly higher than the incidences in the patients with solid tumors trcated with chemotherapeutic agents, in the patients with leukernia (WBC<1, 000/cm3), and in the control patients. Although conventional corticosteroid trcatment do not disseminate the superficial fungal infection, it may perpetuate the low grade dermatophytosis.
복막투석 환자에서 비강 내 Staphylococcus aureus의 보균과 복막염 및 출구감염증에 대한 연구
김치원 ( Chi Weon Kim ),오윤규 ( Yun Kyu Oh ),오국환 ( Kook Hwan Oh ),나기영 ( Ki Young Na ),임춘수 ( Chun Soo Lim ),김연수 ( Yon So Kim ),채동완 ( Dong Wan Chae ),안규리 ( Curie Ahn ),한진석 ( Jin Suk Han ),김성권 ( Suhng Gwon Ki 대한신장학회 2006 Kidney Research and Clinical Practice Vol.25 No.6
이세한(Se Han Lee),이정표(Jung Pyo Lee),김세중(Se Joong Kim),김성균(Seong Gyun Kim),김연수(Yon Su Kim),하종원(Jong Won Ha),안규리(Curie Ahn),김승협(Seung Hyup Kim),한진석(Jin Suk Han),김성권(Suhng Gwon Kim),이현순(Hyun Soon Lee),이정상( 대한신장학회 2002 Kidney Research and Clinical Practice Vol.21 No.5
Renal lymphangiectasia is a rare cystic kidney disorder. This disorder has been termed renal lymphangioma, renal lymphangiomatosis, pararenal lymphatic cyst. We report on a 32-year-old man admitted with complaints of abdominal discomfort, in whom unilateral renal lymphangiectasia with renal vein thrombosis was diagnosed. Abdominal computed tomography revealed left perirenal fluid collection with multiloculation. Left renal vein was completely obliterated due to thrombosis and inferior vena cava (IVC) was partially obliterated. Perirenal fluid collection and renal vein thrombosis were treated initially with percutaneous drainage and anticoagulation therapy. The biochemical features of the drained fluid were compatible with lymphatic fluid. Since there was no decrease in the amount of daily drainage, left nephrectomy and IVC thrombectomy was performed on the 34th day of hospitalization. Left kidney was enlarged (15×10×18 ㎝, 750 g) and composed of numerous smooth, thin-walled cysts. Pathologic diagnosis was renal lymphangiectasia.
급성 신손상을 동반한 중환자에서 지속성 신대체요법의 최적시기 결정을 위한 임상적 인자
김용철 ( Yong Chul Kim ),황진호 ( Jin Ho Hwang ),조은진 ( Eun Jin Cho ),이하정 ( Ha Jeong Lee ),오국환 ( Kook Hwan Oh ),주권욱 ( Kwon Wook Joo ),김연수 ( Yon Su Kim ),안규리 ( Curie Ahn ),한진석 ( Jin Suk Han ),김성권 ( Suhng Gwon 대한신장학회 2011 Kidney Research and Clinical Practice Vol.30 No.6
Purpose: The aim of this study was to evaluate the clinical parameters to determine the optimal time for continuous renal replacement therapy (CRRT) in critically ill patients with severe acute kidney injury (AKI). Methods: A single center retrospective study was performed using data from 166 AKI patients who received CRRT in intensive care unit (ICU) between October 2007 and January 2010. We compared mortality rate at 90 days after the initiation of CRRT, ICU-free and CRRT-free days between "early CRRT" and "late CRRT" groups stratified by blood urea nitrogen (BUN), serum creatinine, urine output and RIFLE criteria. Results: The 90-day mortality rate was significantly lower in the early group compared with the late group when stratified by median value of BUN at the start of CRRT and mean hourly urine output during 6 h, 12 h, and 24 h before CRRT. In addition, the 90-day mortality rate was also significantly lower in patients who received CRRT in the "injury" stage of RIFLE criteria compared with those in "failure" or "loss" stage. ICU-free and CRRT-free days during the first 28 days were significantly longer in the early group when stratified by median level of BUN. However, in terms of creatinine, ICU-free and CRRT-free days were significantly shorter in the early group compared with the late group. CRRTfree days during the first 28 days were also longer in early group stratified by median value of mean hourly urine output during 6 h, 12 h before CRRT. After adjusting for covariates, 90-day mortality was independently lower in the early group defined by median level of BUN (OR=1.65 (1.10- 2.47), p=0.015) and mean hourly urine output during 12h before CRRT (OR=1.56 (1.05-2.33), p=0.027). Conclusion: Our data suggest that early CRRT may have a survival benefit in critically ill patients with severe AKI, and BUN and urine output at the initiation of CRRT may be important parameters to determine the optimal time for CRRT.